65,437 trials
Pain
Primary: Change From Baseline in the Mean Box Scale-11 Pain Review Score at the End of Each Treatment Period (Each Lasting 14-20 Days) — -0.6; -0.6; 0.0 units on a scale — p=0.005
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection. — 56…
Schizophrenia · Schizoaffective Disorder · Bipolar Disorder
Primary: Insulin Sensitivity — 5.55; 1.88 mg glucose/kg.min/μIU insulin — p=<0.05
Pain
Primary: Heart Rate During Treatment With TENS Unit — 137; 131; 133; 133 beats per minute
Gastrointestinal Neoplasm
Primary: Progression Free Survival
Pain
Primary: Efficacy Rate (Percentage) of Patient's Impression — 64.1; 25.9 percentage of participants — p=<0.0001
Heart Failure · Growth Hormone Deficiency · Ischemic Heart Disease
Primary: Peak VO2 — 14.5; 12.9 ml/kg/min
Liver Cirrhosis · Liver Transplant Disorder
Primary: Graft Survival Rate — 100; 94.7; 90; 84 percentage of participants
Coronary Artery Disease · Type 2 Diabetes Mellitus
Primary: Plasminogen Activator Inhibitor 1 — 0.65; 3.82 ng/ml
Metastatic Colorectal Cancer
Primary: Overall Survival — 196; 151 Days — p=0.005178
Infection · Surgical Site Infection
Primary: Percentage of Participants With Success of Prophylaxis — 90.4; 90.3 percentage of participants
Uterine Myomas
Primary: Percentage of Subjects With Reduction of Uterine Bleeding at Week 13 Visit Defined as Pictorial Blood-loss Assessment Chart (PBAC) Score < 75 at End-of-treatment Visit…
Type 2 Diabetes
Primary: Systolic Blood Pressure, Change From Baseline to End of Treatment — -0.5; 9.2 mmHg
Melanoma (Skin)
Primary: Number of Participants With Partial Response — 1 participants
Ventilator-Associated Pneumonia
Primary: Change in Antibiotic Usage or Exposure — 11.87; 7.76 days — p=0.26